ALKS — Alkermes plc

Alkermes Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenues: $496 million, driven by strong performance across the proprietary product portfolio and the first full quarter contribution from LUMRYZ.
• Net Sales: Proprietary products generated $411.7 million, a 34% year-over-year increase.
• Net Income: GAAP net income of $0.5 million; Adjusted EBITDA of $139.2 million.
• R&D Expenses: Increased to $112.9 million, reflecting ongoing development of the orexin portfolio.
• Cash Position: Approximately $690 million in cash and investments at the end of the quarter.
• Guidance for Q3: Expected total revenues between $450 million to $470 million and Adjusted EBITDA between $80 million to $100 million.

2. Strategic Updates and Business Highlights:

• Leadership Transition: Richard Pops will transition to Chairman, with Blair Jackson becoming CEO.
• Orexin Development: Alkermes is advancing alixorexton, an orexin 2 receptor agonist, with ongoing Phase 3 studies in narcolepsy and a Phase 2 study in idiopathic hypersomnia. Two additional orexin compounds, ALKS 7290 (ADHD) and ALKS 4510 (fatigue), are in development.
• LYBALVI Access Expansion: Achieved coverage for over 80% of insured lives through new contracting arrangements, supporting long-term growth.
• VIVITROL: Continued growth with net sales of $124.5 million; no authorized generic expected in 2027 following the termination of the agreement with Amneal.
• LUMRYZ Performance: Generated $96.6 million in net sales, with 3,900 patients on therapy, reflecting strong demand and market penetration.

3. Forward Guidance and Outlook:

• Full-Year Expectations: Reiterating guidance for VIVITROL net sales of $460-$480 million and LYBALVI net sales of $380-$400 million.
• LUMRYZ Forecast: Expected to generate total net sales of $350-$370 million for the year.
• R&D Investment: Anticipating increased R&D expenses as the company advances its orexin pipeline, with a focus on maintaining disciplined financial management.

4. Bad News, Challenges, or Points of Concern:

• Increased R&D Costs: Rising expenses could pressure margins, particularly as the company invests heavily in its orexin pipeline.
• Competitive Landscape: Takeda's upcoming product launch in the orexin space may create pricing pressures and competition for market share.
• Regulatory Uncertainties: Potential challenges in establishing regulatory pathways for new indications and the impact of ongoing discussions around pricing reforms in the U.S. healthcare system.

5. Notable Q&A Insights:

• ADHD Development: The company plans to start with adult patients before expanding to pediatrics, with a focus on establishing a titration strategy based on learnings from narcolepsy.
• Combination Therapy Interest: There is significant interest in combining orexins with existing oxybate therapies, and Alkermes plans to generate data to support this approach.
• Market Size for IH: There is an acknowledgment of a potentially larger market for idiopathic hypersomnia than previously estimated, driven by unmet patient needs.
• Pricing Strategy: The pricing for alixorexton will be influenced by Takeda's pricing strategy, with a focus on delivering value to patients.

Overall, Alkermes demonstrated strong financial performance in Q2 2026, with significant advancements in its orexin pipeline and strategic initiatives to enhance its product offerings. However, the company faces challenges from competitive pressures and rising R&D costs as it seeks to capitalize on its growth opportunities.